Compare Chugai Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 23.71%
- Healthy long term growth as Net Sales has grown by an annual rate of 11.43% and Operating profit at 19.46%
- Company has very low debt and has enough cash to service the debt requirements
2
The company has declared Positive results for the last 4 consecutive quarters
3
With ROE of 21.74%, it has a attractive valuation with a 6.45 Price to Book Value
4
Majority shareholders : Non Institution
Stock DNA
Pharmaceuticals & Biotechnology
JPY 13,855,584 Million (Large Cap)
30.00
NA
0.02%
-0.47
22.39%
7.33
Revenue and Profits:
Net Sales:
290,005 Million
(Quarterly Results - Jun 2025)
Net Profit:
97,155 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.29%
0%
31.29%
6 Months
23.11%
0%
23.11%
1 Year
35.1%
0%
35.1%
2 Years
77.96%
0%
77.96%
3 Years
168.41%
0%
168.41%
4 Years
129.3%
0%
129.3%
5 Years
73.23%
0%
73.23%
Chugai Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.43%
EBIT Growth (5y)
19.46%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.50
Sales to Capital Employed (avg)
0.67
Tax Ratio
29.16%
Dividend Payout Ratio
41.63%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
52.96%
ROE (avg)
23.71%
Valuation key factors
Factor
Value
P/E Ratio
30
Industry P/E
Price to Book Value
6.45
EV to EBIT
19.52
EV to EBITDA
19.42
EV to Capital Employed
11.81
EV to Sales
9.30
PEG Ratio
1.23
Dividend Yield
0.01%
ROCE (Latest)
60.50%
ROE (Latest)
21.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
290,005.00
288,459.00
0.54%
Operating Profit (PBDIT) excl Other Income
148,362.00
146,872.00
1.01%
Interest
0.00
0.00
Exceptional Items
-12,400.00
-2,400.00
-416.67%
Consolidate Net Profit
97,155.00
97,234.00
-0.08%
Operating Profit Margin (Excl OI)
483.70%
481.40%
0.23%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 0.54% vs -4.51% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -0.08% vs 6.20% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,170,611.00
1,111,367.00
5.33%
Operating Profit (PBDIT) excl Other Income
575,572.00
447,405.00
28.65%
Interest
95.00
82.00
15.85%
Exceptional Items
-8,992.00
-15,310.00
41.27%
Consolidate Net Profit
387,317.00
325,472.00
19.00%
Operating Profit Margin (Excl OI)
464.60%
374.00%
9.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 5.33% vs -11.79% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 19.00% vs -13.08% in Dec 2023
About Chugai Pharmaceutical Co., Ltd. 
Chugai Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






